Efficacy and Safety of Tazarotene Gel in Nail Psoriasis

• Status: Completed
• Trial end date: 2015-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to determine the efficacy and safety of topical application of the gel compared to placebo in nail psoriasis.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Almirall, S.A.
• Treatments: Nicotinic Acids; Tazarotene

Criteria

Inclusion Criteria:

• Key inclusion criteria:

• Mild to moderate nail psoriasis on at least one fingernail

Exclusion Criteria:

Key exclusion criteria:

• any other skin condition, with a potential to affect the nails or to interfere with evaluation of the disease;

• history of hypersensitivity to retinoids or to other components of the trial medication

• topical treatment of nails with antipsoriatics in the 4 weeks preceding the treatment phase;

• systemic treatment of psoriasis within the three months before the treatment phase of the trial or during the trial

• intralesional steroid injection before the treatment phase of the trial

• phototherapy before the treatment phase of the trial;

• any chronic infection or condition capable of interfering with the conduct of the trial;

• evidence of drug or alcohol abuse;

• symptoms of a clinically significant illness that may influence the outcome of the trial in the four weeks preceding the treatment phase of the trial;

• participation in another clinical trial within the last 4 weeks prior to first treatment in this clinical trial;

• pregnancy or nursing;